NTLA
NASDAQIntellia Therapeutics Inc.
Price$13.54-0.28 (-2.03%)
2026-03-042026-06-05
News · 26 weeks62-88%
2025-12-142026-06-07
Mix2390d
- Other9(39%)
- SEC Filings9(39%)
- Offering3(13%)
- Leadership1(4%)
- Earnings1(4%)
Latest news
25 items- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on June 1, 2026, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 47,150 shares of Intellia's common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee's continued service as an employee of, or
- PRIntellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that data from the global Phase 3 HAELO clinical trial of lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE) will be presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place June 12-15 in Istanbul, Türkiye. Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States. Late-Brea
- SECSEC Form 10-Q filed by Intellia Therapeutics Inc.10-Q - Intellia Therapeutics, Inc. (0001652130) (Filer)
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRIntellia Therapeutics Announces First Quarter 2026 Financial Results and Business UpdatesPresented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z in ATTR-CM and ATTRv-PN, respectivelyIncluding proceeds from underwritten public offering in April, existing cash resources expected to fund operations at least into 2028 CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial resu
- PRIntellia Therapeutics to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that management will be participating in fireside chats at the following upcoming investor conferences: Bank of America Securities Health Care ConferenceDate: Tuesday, May 12, 2026Fireside Chat Time: 3:40 p.m. PTLocation: Las Vegas RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 20, 2026Fireside Chat Time: 2:35 p.m. ETLocation: New York Jefferies Global Healthcare ConferenceDate: Wednesday, June 3, 2026Fireside Chat Time: 4:55 p
- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on May 1, 2026, it awarded inducement grants to 43 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 208,850 shares of Intellia's common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee's continued service as an employee of, or
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- SECSEC Form DEFA14A filed by Intellia Therapeutics Inc.DEFA14A - Intellia Therapeutics, Inc. (0001652130) (Filer)
- SECSEC Form DEF 14A filed by Intellia Therapeutics Inc.DEF 14A - Intellia Therapeutics, Inc. (0001652130) (Filer)
- SECSEC Form 424B5 filed by Intellia Therapeutics Inc.424B5 - Intellia Therapeutics, Inc. (0001652130) (Filer)
- SECSEC Form SCHEDULE 13G filed by Intellia Therapeutics Inc.SCHEDULE 13G - Intellia Therapeutics, Inc. (0001652130) (Subject)
- PRIntellia Therapeutics Announces Pricing of Public Offering of Common StockCAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the pricing of an underwritten public offering of 16,744,187 shares of its common stock. The shares of common stock are being sold at a public offering price of $10.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $180 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the securities in the
- SECSEC Form 424B5 filed by Intellia Therapeutics Inc.424B5 - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRIntellia Announces Proposed Public Offering of Common StockCAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Intellia. Jefferies, Goldman Sachs & Co. LLC and Citigroup are acting as joint book-running managers for the pr
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRIntellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene EditingPhase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and ongoing therapy for six-month efficacy evaluation period, demonstrating its potential to be the first and only one-time HAE treatmentRolling biologics license application (BLA) submission initiated with the U.S. Food and Drug Administration (FDA); anticipate U.S. launch in the first half of 2027, if approvedIntellia to host webcast today at 8:00 a.m. ET CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical comp
- PRIntellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary AngioedemaCAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced it has initiated a rolling submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of lonvo-z (formerly known as NTLA-2002) for hereditary angioedema (HAE). Designed as a one-time treatment that is administered in an outpatient setting, lonvo-z is an in vivo CRISPR gene editing candidate that is intended to inactivate the kallikrein B1 (KLKB1) gene to permanently lower kallikrein and bradyki
- PRIntellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026World's first Phase 3 readout for an in vivo CRISPR gene editing candidateCompany to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data. To join the webcast, please visit the Events page of the Inv
- SECSEC Form 8-K filed by Intellia Therapeutics Inc.8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRThe Credibility Filter Wall Street Uses to Sort Biotech WinnersVANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid or late stage clinical data[1]. That is not a coincidence. The IQVIA Institute's latest annual report found that biopharma dealmaking is now clustering around high value science and companies with credentialed pipelines[2]. It's becoming apparent that smart money is no longer chasing press releases, it's chasing invitations. Conference stage presentations from field defining researchers, peer reviewed journal publications, and stacked regulatory designations have become the fi
- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on April 1, 2026, it awarded inducement grants to 13 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 67,150 shares of Intellia's common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee's continued service as an employee of, o
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Intellia Therapeutics Inc.SCHEDULE 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on March 1, 2026, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 16,500 shares of Intellia's common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee's continued service as an employee of, or other serv
- INSIDEREVP, General Counsel Basta James was granted 46,080 shares and sold $16,688 worth of shares (1,211 units at $13.78), increasing direct ownership by 40% to 156,794 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
NTLA FAQ
7 questionsWhat does Intellia Therapeutics Inc. do?
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline...Where does NTLA stock trade?
Intellia Therapeutics Inc. (NTLA) is listed on NASDAQ.What sector and industry is NTLA in?
Intellia Therapeutics Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Intellia Therapeutics Inc. go public?
Intellia Therapeutics Inc. (NTLA) completed its IPO in 2016.What are analysts saying about NTLA?
Intellia Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-03-02. Recent price targets range from $500.00 to $1400.00.What companies are similar to NTLA?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), ORKA (Oruka Therapeutics Inc.), NNNN (Anbio Biotechnology). Compare NTLA side-by-side with any of them on Quantisnow.How can I track NTLA on Quantisnow?
Quantisnow aggregates Intellia Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NTLA to receive live email and push alerts on every new disclosure.